Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

Peter Dreger; Johannes Schetelig; Niels Andersen; Paolo Corradini; Michel van Gelder; John Gribben; Eva Kimby; Mauricette Michallet; Carol Moreno; Stephan Stilgenbauer; Emili Montserrat

doi:10.1182/blood-2014-07-586826

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

Peter Dreger^*, Johannes Schetelig, Niels Andersen, Paolo Corradini, Michel van Gelder, John Gribben, Eva Kimby, Mauricette Michallet, Carol Moreno, Stephan Stilgenbauer, Emili Montserrat

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (HR-CLL; ie, refractory to purine analogs, short response [

Original language	English
Pages (from-to)	3841-3849
Journal	Blood
Volume	124
Issue number	26
DOIs	https://doi.org/10.1182/blood-2014-07-586826
Publication status	Published - 18 Dec 2014

Access to Document

10.1182/blood-2014-07-586826

Cite this

@article{eac03d144b29461693cd59b6a02289e0,

title = "Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?",

abstract = "Allogeneic hematopoietic stem cell transplantation (HSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (HR-CLL; ie, refractory to purine analogs, short response [",

author = "Peter Dreger and Johannes Schetelig and Niels Andersen and Paolo Corradini and {van Gelder}, Michel and John Gribben and Eva Kimby and Mauricette Michallet and Carol Moreno and Stephan Stilgenbauer and Emili Montserrat",

year = "2014",

month = dec,

day = "18",

doi = "10.1182/blood-2014-07-586826",

language = "English",

volume = "124",

pages = "3841--3849",

journal = "Blood",

issn = "0006-4971",